
PPADS tetrasodium
CAS No. 192575-19-2
PPADS tetrasodium( —— )
Catalog No. M33471 CAS No. 192575-19-2
PPADS tetrasodiuma is a potent P2X receptor antagonist and inhibitor of the inverse mode of Na/Ca2? exchange in guinea pig airway smooth muscle and is neuroprotective against glutamate/NMDA toxicity.PPADS tetrasodiuma inhibits P2X1, P2X-2, P2X-3, and P2X- 5. 5.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 67 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePPADS tetrasodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionPPADS tetrasodiuma is a potent P2X receptor antagonist and inhibitor of the inverse mode of Na/Ca2? exchange in guinea pig airway smooth muscle and is neuroprotective against glutamate/NMDA toxicity.PPADS tetrasodiuma inhibits P2X1, P2X-2, P2X-3, and P2X- 5. 5.
-
DescriptionPPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca2+ exchanger in guinea pig airway smooth muscle.
-
In VitroPPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner.PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and is highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ~1-3 and ~30 μM for the hP2X4R.
-
In VivoPPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hoursfor 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis.Animal Model:Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode)Dosage:15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW Administration:i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.)Result:Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetP2X Receptor
-
RecptorP2X Receptor | Na+/Ca2+ Exchanger
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number192575-19-2
-
Formula Weight599.3
-
Molecular FormulaC14H10N3Na4O12PS2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 50 mg/mL (83.43 mM; Ultrasonic)
-
SMILESO=CC1=C(C(C)=NC(N=NC2=CC=C(S(=O)([O-])=O)C=C2S(=O)([O-])=O)=C1COP([O-])([O-])=O)O.[Na+].[Na+].[Na+].[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na?/Ca2? exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44.?
molnova catalog



related products
-
Brilliant blue G-250
Brilliant Blue G is an antagonist of the P2X7 purinergic receptor.
-
AZ10606120 dihydroch...
AZ10606120 dihydrochloride has anti-depressant effects and reduces tumour growth.
-
Lu AF27139
Lu AF27139 is an effective and selective antagonist of P2X7 receptor (IC50s of 12 and 2.4 nM for human and rat, Kis of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 can be used in CNS diseases studies.